Turnstone Bio Goes IPO to Fund Clinical Tests of New Kind of Cancer Cell Therapy
Turnstone Biologics isn’t the only cell therapy biotech focused on tumor-infiltrating lymphocytes. With $80 million in IPO cash, it can continue clinical trials that could show whether its approach to TILs has advantages.
